Healthcare Industry News: Ventana
News Release - October 10, 2007
Transgenomic Names New Sr. VP of Sales and MarketingOMAHA, Neb.--(HSMN NewsFeed)--Transgenomic, Inc. (OTCBB:TBIO ), today announced that Chad M. Richards has joined its executive management team as Senior Vice President of Sales and Marketing. He will be responsible for managing the Company's sales and marketing functions worldwide.
Mr. Richards brings a significant breadth of sales management and marketing experience within the diagnostic testing sector. Before joining Transgenomic, he served as National Sales Director, Cancer Diagnostics Division for Quest Diagnostics, the nation's leading provider of diagnostic testing, information and services. During his career with Quest Diagnostics, Mr. Richards held a variety of sales management roles in both their Physician and Hospital business segments. Prior to that, he held different Marketing and Sales Management roles with Ventana Medical Systems, one of the world's leading developers and manufacturers of oncology diagnostic instrument and reagent systems.
"Chad brings significant experience to this position including a successful track record in both Reference Laboratory and Diagnostic Equipment sales," said Craig Tuttle, Transgenomic President and Chief Executive Officer. "His unique expertise and proven track record will be of tremendous value as we pursue the growth opportunities we see in the 3 key areas of our business model. We are excited to have him on board to lead our global sales and marketing initiatives as we accelerate our growth and take the company into profitability."
About Transgenomic: A decade of discovery 1997 - 2007
Transgenomic is a global biotechnology company that provides unique products and services of automated high sensitivity genetic variation and mutation analysis. Their offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine. Specific offerings include WAVEŽ DHPLC Systems, related consumables and assay kits, cytogenetics automated systems, and Transgenomic Discovery and CLIA Lab Services. Transgenomic Discovery and Lab Services utilize their technology and expertise to provide a menu of mutation scanning tests for over 700 cancer-associated genes and more than 60 validated diagnostic tests to meet the needs of pharmaceutical and biotech companies, research and clinical laboratories, physicians and patients. For more information about the innovative systems, products and services offered by Transgenomic, please visit: www.transgenomic.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.